Source: Fortune
Summary
The FDA is set to review seven peptides for possible approval to be legally mixed by specialty pharmacies, which could lead to a new multibillion-dollar market in telehealth. Companies like Hims & Hers are preparing to expand access to peptides, despite concerns over safety data. The market for peptides is estimated to be around $30 billion, with many users stacking multiple compounds at once. Telehealth infrastructure companies like Wheel predict a flood of copycat sites launching peptide programs, followed by consolidation.
Our Reading
The numbers tell one story.
Hims & Hers is diversifying its offerings after its stock got hammered due to FDA proposals excluding GLP-1 drugs from pharmacy compounding lists. The company’s chief medical officer will testify at the FDA hearing on peptides. Telehealth infrastructure companies like Wheel predict a flood of copycat sites launching peptide programs, followed by consolidation. The market for peptides is estimated to be around $30 billion. The FDA’s decision could create a new multibillion-dollar market in telehealth.
The announcement sounds like a familiar phase: regulatory uncertainty creates a gray market, which eventually gets legitimized.
Author: Evan Null
